BIOTIE THERAPIES CORP 
By BIOTIE THERAPIES CORP. Stock Exchange Release January 3, 2014 at 9.00 am
Issue of new treasury shares of Biotie Therapies Corp without consideration
Pursuant to the authorization of the Annual General Meeting of Shareholders held on 4 April 2013, the Board of Directors of Biotie Therapies Corp. has resolved to issue 3,321,660 shares ("Treasury Shares") to the Company itself without consideration in accordance with Chapter 9 Section 20 of the Finnish Companies Act (624/2006, as amended). The Treasury Shares are issued for the purposes of being conveyed to employees entitled to them pursuant to the terms and conditions of the Stock Option Plan 2011 and the Equity Incentive Plan 2011 ("Plans"). The Treasury Shares are of the same class as the existing shares in the Company.
The Treasury Shares will be registered without delay so that the Treasury Shares will be entered into the Finnish Trade Register on or about 8 January 2014. An application will be filed for registration of the Treasury Shares in the book-entry system maintained by Euroclear Finland Ltd, and to apply for listing of the Treasury Shares in NASDAQ OMX Helsinki Ltd after the Treasury Shares have been registered.
After the registration of the Treasury Shares with the Finnish Trade Register, Biotie will have 456,032,398 shares in total of which 446,213,948 will be outstanding shares. Should all the Treasury Shares issued be conveyed to employees pursuant to the Plans, then this will represent a 0.74 per cent of the current outstanding shares. The total number of the Company's shares after the share issue held by the Company or its fully owned subsidiary is 9,818,450 shares (2.15 per cent).
It is expected that under the terms of the Plans the Treasury Shares will be conveyed to employees at a number of times during the period January 2014 to February 2015. The Company will publish releases on conveyance of shares separately when necessary.
Turku, 3 January 2014
Biotie Therapies Corp.
Timo Veromaa, President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com:
mailto:virve.nurmi@biotie.com
www.biotie.com
DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire
